Lucid Diagnostics Inc. (NASDAQ: LUCD) Stock Competitors & Peer Comparison
See LUCD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LUCD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LUCD | $0.95 | -5.74% | 183.2M | -2.60 | -$0.37 | N/A |
| ABT | $116.09 | +1.45% | 197.7B | 21.93 | $5.21 | +2.16% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $329.58 | -3.06% | 125.6B | 24.48 | $13.39 | +1.05% |
| MDT | $93.09 | -1.10% | 118.2B | 16.70 | $5.53 | +3.08% |
| BSX | $50.33 | -3.23% | 73.4B | 15.93 | $3.10 | N/A |
| EW | $90.14 | -2.32% | 51.7B | 33.26 | $2.70 | N/A |
| DXCM | $91.03 | +1.28% | 34B | 38.72 | $2.33 | N/A |
| RMD | $232.77 | +1.21% | 33.1B | 21.22 | $10.77 | +1.07% |
| PHG | $27.50 | +1.46% | 27B | 15.78 | $1.75 | +3.59% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
LUCD vs ABT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ABT has a market cap of 197.7B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ABT trades at $116.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ABT's P/E ratio is 21.93. In terms of profitability, LUCD's ROE is -4.04%, compared to ABT's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
LUCD vs BSX-PA Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, LUCD's ROE is -4.04%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
LUCD vs SYK Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SYK has a market cap of 125.6B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SYK trades at $329.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SYK's P/E ratio is 24.48. In terms of profitability, LUCD's ROE is -4.04%, compared to SYK's ROE of +0.16%. Regarding short-term risk, LUCD is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SYK's competition here
Medtronic plc (NYSE: MDT)
LUCD vs MDT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, MDT has a market cap of 118.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while MDT trades at $93.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas MDT's P/E ratio is 16.70. In terms of profitability, LUCD's ROE is -4.04%, compared to MDT's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
LUCD vs BSX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BSX has a market cap of 73.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BSX trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BSX's P/E ratio is 15.93. In terms of profitability, LUCD's ROE is -4.04%, compared to BSX's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
LUCD vs EW Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while EW trades at $90.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas EW's P/E ratio is 33.26. In terms of profitability, LUCD's ROE is -4.04%, compared to EW's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
LUCD vs DXCM Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, DXCM has a market cap of 34B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while DXCM trades at $91.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas DXCM's P/E ratio is 38.72. In terms of profitability, LUCD's ROE is -4.04%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, LUCD is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
LUCD vs RMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, RMD has a market cap of 33.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while RMD trades at $232.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas RMD's P/E ratio is 21.22. In terms of profitability, LUCD's ROE is -4.04%, compared to RMD's ROE of +0.24%. Regarding short-term risk, LUCD is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
LUCD vs PHG Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PHG has a market cap of 27B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PHG trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PHG's P/E ratio is 15.78. In terms of profitability, LUCD's ROE is -4.04%, compared to PHG's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
LUCD vs ZBH Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ZBH has a market cap of 19.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ZBH trades at $100.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ZBH's P/E ratio is 11.68. In terms of profitability, LUCD's ROE is -4.04%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, LUCD is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
LUCD vs ABMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ABMD's P/E ratio is 65.36. In terms of profitability, LUCD's ROE is -4.04%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
LUCD vs PEN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PEN trades at $325.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PEN's P/E ratio is 84.57. In terms of profitability, LUCD's ROE is -4.04%, compared to PEN's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
LUCD vs SWAV Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SWAV's P/E ratio is 78.76. In terms of profitability, LUCD's ROE is -4.04%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, LUCD is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
LUCD vs SNN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SNN trades at $29.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SNN's P/E ratio is 13.66. In terms of profitability, LUCD's ROE is -4.04%, compared to SNN's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SNN's competition here
Globus Medical, Inc. (NYSE: GMED)
LUCD vs GMED Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while GMED trades at $86.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas GMED's P/E ratio is 19.30. In terms of profitability, LUCD's ROE is -4.04%, compared to GMED's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check GMED's competition here
Align Technology, Inc. (NASDAQ: ALGN)
LUCD vs ALGN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ALGN trades at $159.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ALGN's P/E ratio is 14.49. In terms of profitability, LUCD's ROE is -4.04%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
LUCD vs GKOS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, GKOS has a market cap of 10.9B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while GKOS trades at $185.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas GKOS's P/E ratio is -214.73. In terms of profitability, LUCD's ROE is -4.04%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, LUCD is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
LUCD vs PODD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PODD has a market cap of 10.5B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PODD trades at $148.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PODD's P/E ratio is 25.81. In terms of profitability, LUCD's ROE is -4.04%, compared to PODD's ROE of +0.27%. Regarding short-term risk, LUCD is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
LUCD vs BIO Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BIO has a market cap of 10.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BIO trades at $378.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BIO's P/E ratio is 40.57. In terms of profitability, LUCD's ROE is -4.04%, compared to BIO's ROE of +0.03%. Regarding short-term risk, LUCD is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
LUCD vs BIO-B Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BIO-B has a market cap of 10B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BIO-B trades at $365.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BIO-B's P/E ratio is -64.28. In terms of profitability, LUCD's ROE is -4.04%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, LUCD is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
LUCD vs MASI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas MASI's P/E ratio is 44.43. In terms of profitability, LUCD's ROE is -4.04%, compared to MASI's ROE of +0.09%. Regarding short-term risk, LUCD is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
LUCD vs BRKR Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BRKR trades at $59.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BRKR's P/E ratio is 30.11. In terms of profitability, LUCD's ROE is -4.04%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, LUCD is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
LUCD vs HAE Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while HAE trades at $108.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas HAE's P/E ratio is 21.59. In terms of profitability, LUCD's ROE is -4.04%, compared to HAE's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
LUCD vs NARI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas NARI's P/E ratio is -59.24. In terms of profitability, LUCD's ROE is -4.04%, compared to NARI's ROE of -0.00%. Regarding short-term risk, LUCD is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
LUCD vs LIVN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while LIVN trades at $78.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas LIVN's P/E ratio is 18.58. In terms of profitability, LUCD's ROE is -4.04%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
LUCD vs ITGR Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ITGR trades at $125.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ITGR's P/E ratio is 19.72. In terms of profitability, LUCD's ROE is -4.04%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, LUCD is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
LUCD vs IRTC Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while IRTC trades at $125.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas IRTC's P/E ratio is -199.97. In terms of profitability, LUCD's ROE is -4.04%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, LUCD is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
LUCD vs AXNX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas AXNX's P/E ratio is -709.80. In terms of profitability, LUCD's ROE is -4.04%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
LUCD vs TMDX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while TMDX trades at $94.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas TMDX's P/E ratio is 46.12. In terms of profitability, LUCD's ROE is -4.04%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, LUCD is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
LUCD vs AXGN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while AXGN trades at $47.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas AXGN's P/E ratio is 122.21. In terms of profitability, LUCD's ROE is -4.04%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, LUCD is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
LUCD vs BFLY Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BFLY trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BFLY's P/E ratio is -38.19. In terms of profitability, LUCD's ROE is -4.04%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, LUCD is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
LUCD vs UFPT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while UFPT trades at $306.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas UFPT's P/E ratio is 31.08. In terms of profitability, LUCD's ROE is -4.04%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, LUCD is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
LUCD vs ESTA Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ESTA trades at $71.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ESTA's P/E ratio is -56.76. In terms of profitability, LUCD's ROE is -4.04%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, LUCD is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
LUCD vs NUVA Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas NUVA's P/E ratio is 75.00. In terms of profitability, LUCD's ROE is -4.04%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
LUCD vs NVCR Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while NVCR trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas NVCR's P/E ratio is -11.61. In terms of profitability, LUCD's ROE is -4.04%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, LUCD is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
LUCD vs INSP Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while INSP trades at $62.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas INSP's P/E ratio is 26.96. In terms of profitability, LUCD's ROE is -4.04%, compared to INSP's ROE of +0.18%. Regarding short-term risk, LUCD is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
LUCD vs TNDM Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while TNDM trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas TNDM's P/E ratio is -20.52. In terms of profitability, LUCD's ROE is -4.04%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, LUCD is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
LUCD vs CNMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CNMD trades at $51.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CNMD's P/E ratio is 11.29. In terms of profitability, LUCD's ROE is -4.04%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, LUCD is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CNMD's competition here
Enovis Corporation (NYSE: ENOV)
LUCD vs ENOV Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ENOV trades at $25.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ENOV's P/E ratio is 7.50. In terms of profitability, LUCD's ROE is -4.04%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, LUCD is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ENOV's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
LUCD vs ATEC Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ATEC trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ATEC's P/E ratio is -154.83. In terms of profitability, LUCD's ROE is -4.04%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, LUCD is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ATEC's competition here
Artivion, Inc. (NYSE: AORT)
LUCD vs AORT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while AORT trades at $28.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas AORT's P/E ratio is 46.60. In terms of profitability, LUCD's ROE is -4.04%, compared to AORT's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
LUCD vs HSKA Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas HSKA's P/E ratio is -62.49. In terms of profitability, LUCD's ROE is -4.04%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, LUCD is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
LUCD vs IART Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while IART trades at $16.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas IART's P/E ratio is 7.03. In terms of profitability, LUCD's ROE is -4.04%, compared to IART's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
LUCD vs PRCT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PRCT trades at $21.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PRCT's P/E ratio is -10.69. In terms of profitability, LUCD's ROE is -4.04%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, LUCD is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
LUCD vs AVNS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas AVNS's P/E ratio is 27.77. In terms of profitability, LUCD's ROE is -4.04%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, LUCD is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
LUCD vs LMRI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while LMRI trades at $11.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas LMRI's P/E ratio is -22.73. In terms of profitability, LUCD's ROE is -4.04%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, LUCD is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
LUCD vs SILK Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SILK's P/E ratio is -18.96. In terms of profitability, LUCD's ROE is -4.04%, compared to SILK's ROE of -0.35%. Regarding short-term risk, LUCD is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
LUCD vs IRMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while IRMD trades at $87.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas IRMD's P/E ratio is 43.56. In terms of profitability, LUCD's ROE is -4.04%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, LUCD is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
LUCD vs FNA Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas FNA's P/E ratio is -19.83. In terms of profitability, LUCD's ROE is -4.04%, compared to FNA's ROE of -0.35%. Regarding short-term risk, LUCD is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
LUCD vs BVS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BVS has a market cap of 970.8M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BVS trades at $14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BVS's P/E ratio is 18.86. In terms of profitability, LUCD's ROE is -4.04%, compared to BVS's ROE of +0.28%. Regarding short-term risk, LUCD is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
LUCD vs CBLL Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CBLL has a market cap of 922.4M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CBLL trades at $24.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CBLL's P/E ratio is -14.91. In terms of profitability, LUCD's ROE is -4.04%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, LUCD is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CBLL's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
LUCD vs AVR Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, AVR has a market cap of 899.4M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while AVR trades at $9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas AVR's P/E ratio is -4.15. In terms of profitability, LUCD's ROE is -4.04%, compared to AVR's ROE of -0.78%. Regarding short-term risk, LUCD is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AVR's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
LUCD vs BBNX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BBNX has a market cap of 876.4M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BBNX trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BBNX's P/E ratio is -12.90. In terms of profitability, LUCD's ROE is -4.04%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, LUCD is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check BBNX's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
LUCD vs SIBN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SIBN has a market cap of 863.9M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SIBN trades at $19.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SIBN's P/E ratio is -57.29. In terms of profitability, LUCD's ROE is -4.04%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, LUCD is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
LUCD vs INMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, INMD has a market cap of 857.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while INMD trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas INMD's P/E ratio is 10.36. In terms of profitability, LUCD's ROE is -4.04%, compared to INMD's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
LUCD vs CSII Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CSII's P/E ratio is -20.83. In terms of profitability, LUCD's ROE is -4.04%, compared to CSII's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
LUCD vs VREX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, VREX has a market cap of 778.4M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas VREX's P/E ratio is 19.46. In terms of profitability, LUCD's ROE is -4.04%, compared to VREX's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
LUCD vs AHCO Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, AHCO has a market cap of 733.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while AHCO trades at $5.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas AHCO's P/E ratio is 11.00. In terms of profitability, LUCD's ROE is -4.04%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, LUCD is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
LUCD vs SSII Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SSII has a market cap of 722.5M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SSII trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SSII's P/E ratio is -70.41. In terms of profitability, LUCD's ROE is -4.04%, compared to SSII's ROE of -0.27%. Regarding short-term risk, LUCD is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
LUCD vs KIDS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, KIDS has a market cap of 673.7M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while KIDS trades at $25.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas KIDS's P/E ratio is -22.23. In terms of profitability, LUCD's ROE is -4.04%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, LUCD is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
LUCD vs SRDX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SRDX's P/E ratio is -34.66. In terms of profitability, LUCD's ROE is -4.04%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, LUCD is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
LUCD vs CTKB Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CTKB trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CTKB's P/E ratio is -24.69. In terms of profitability, LUCD's ROE is -4.04%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, LUCD is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CTKB's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
LUCD vs BWAY Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BWAY has a market cap of 587.2M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BWAY trades at $14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BWAY's P/E ratio is 38.03. In terms of profitability, LUCD's ROE is -4.04%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, LUCD is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BWAY's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
LUCD vs APEN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas APEN's P/E ratio is -9.43. In terms of profitability, LUCD's ROE is -4.04%, compared to APEN's ROE of -0.85%. Regarding short-term risk, LUCD is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
LUCD vs DCTH Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, DCTH has a market cap of 578.2M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while DCTH trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas DCTH's P/E ratio is 1675.00. In terms of profitability, LUCD's ROE is -4.04%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, LUCD is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check DCTH's competition here
Cerus Corporation (NASDAQ: CERS)
LUCD vs CERS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CERS has a market cap of 562.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CERS trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CERS's P/E ratio is -55.69. In terms of profitability, LUCD's ROE is -4.04%, compared to CERS's ROE of -0.10%. Regarding short-term risk, LUCD is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CERS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
LUCD vs ZIMV Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, LUCD's ROE is -4.04%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
LUCD vs TCMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, TCMD has a market cap of 528.5M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while TCMD trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas TCMD's P/E ratio is 26.63. In terms of profitability, LUCD's ROE is -4.04%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
LUCD vs NPCE Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, NPCE has a market cap of 478M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while NPCE trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas NPCE's P/E ratio is -24.60. In terms of profitability, LUCD's ROE is -4.04%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, LUCD is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
LUCD vs CLPT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CLPT has a market cap of 455.5M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CLPT trades at $15.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CLPT's P/E ratio is -12.87. In terms of profitability, LUCD's ROE is -4.04%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, LUCD is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CLPT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
LUCD vs CARL Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CARL has a market cap of 448.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CARL trades at $16.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CARL's P/E ratio is -11.54. In terms of profitability, LUCD's ROE is -4.04%, compared to CARL's ROE of -0.38%. Regarding short-term risk, LUCD is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check CARL's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
LUCD vs SGHT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SGHT has a market cap of 443.4M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SGHT trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SGHT's P/E ratio is -14.55. In terms of profitability, LUCD's ROE is -4.04%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, LUCD is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
LUCD vs OFIX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, OFIX has a market cap of 404.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while OFIX trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas OFIX's P/E ratio is -13.08. In terms of profitability, LUCD's ROE is -4.04%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check OFIX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
LUCD vs PACB Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PACB has a market cap of 382M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PACB trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PACB's P/E ratio is -3.00. In terms of profitability, LUCD's ROE is -4.04%, compared to PACB's ROE of -49.62%. Regarding short-term risk, LUCD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
LUCD vs SENS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SENS has a market cap of 368.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SENS trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SENS's P/E ratio is -4.41. In terms of profitability, LUCD's ROE is -4.04%, compared to SENS's ROE of -1.66%. Regarding short-term risk, LUCD is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check SENS's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
LUCD vs CATX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CATX has a market cap of 367.2M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CATX trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CATX's P/E ratio is -2.42. In terms of profitability, LUCD's ROE is -4.04%, compared to CATX's ROE of -0.42%. Regarding short-term risk, LUCD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check CATX's competition here
Picard Medical, Inc. (AMEX: PMI)
LUCD vs PMI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PMI has a market cap of 333.8M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PMI trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PMI's P/E ratio is -2.71. In terms of profitability, LUCD's ROE is -4.04%, compared to PMI's ROE of -9.31%. Regarding short-term risk, LUCD is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check PMI's competition here
Electromed, Inc. (AMEX: ELMD)
LUCD vs ELMD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ELMD has a market cap of 333.1M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ELMD trades at $39.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ELMD's P/E ratio is 34.39. In terms of profitability, LUCD's ROE is -4.04%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, LUCD is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
LUCD vs TLSI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, TLSI has a market cap of 322M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while TLSI trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas TLSI's P/E ratio is -3.11. In terms of profitability, LUCD's ROE is -4.04%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, LUCD is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
LUCD vs SMLR Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas SMLR's P/E ratio is 3.92. In terms of profitability, LUCD's ROE is -4.04%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, LUCD is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SMLR's competition here
CapsoVision, Inc. (NASDAQ: CV)
LUCD vs CV Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, CV has a market cap of 295.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while CV trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas CV's P/E ratio is -2.36. In terms of profitability, LUCD's ROE is -4.04%, compared to CV's ROE of -1.78%. Regarding short-term risk, LUCD is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CV's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
LUCD vs TMCI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, TMCI has a market cap of 289.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while TMCI trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas TMCI's P/E ratio is -4.74. In terms of profitability, LUCD's ROE is -4.04%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, LUCD is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TMCI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
LUCD vs ANIK Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ANIK has a market cap of 285.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ANIK trades at $21.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ANIK's P/E ratio is 43.55. In terms of profitability, LUCD's ROE is -4.04%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, LUCD is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
LUCD vs RXST Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, RXST has a market cap of 252.1M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while RXST trades at $6.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas RXST's P/E ratio is -6.55. In terms of profitability, LUCD's ROE is -4.04%, compared to RXST's ROE of -0.17%. Regarding short-term risk, LUCD is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
LUCD vs RCEL Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, RCEL has a market cap of 250.7M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while RCEL trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas RCEL's P/E ratio is -6.43. In terms of profitability, LUCD's ROE is -4.04%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, LUCD is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check RCEL's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
LUCD vs MGRM Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas MGRM's P/E ratio is -12.00. In terms of profitability, LUCD's ROE is -4.04%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, LUCD is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
LUCD vs PROF Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, PROF has a market cap of 241.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while PROF trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas PROF's P/E ratio is -5.36. In terms of profitability, LUCD's ROE is -4.04%, compared to PROF's ROE of -0.56%. Regarding short-term risk, LUCD is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check PROF's competition here
Nevro Corp. (NYSE: NVRO)
LUCD vs NVRO Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas NVRO's P/E ratio is -1.91. In terms of profitability, LUCD's ROE is -4.04%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, LUCD is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
LUCD vs STIM Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, STIM has a market cap of 215M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while STIM trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas STIM's P/E ratio is -5.72. In terms of profitability, LUCD's ROE is -4.04%, compared to STIM's ROE of -1.51%. Regarding short-term risk, LUCD is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
LUCD vs BSGM Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas BSGM's P/E ratio is -5.81. In terms of profitability, LUCD's ROE is -4.04%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, LUCD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
LUCD vs MDGS Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas MDGS's P/E ratio is -0.27. In terms of profitability, LUCD's ROE is -4.04%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, LUCD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
LUCD vs QIPT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas QIPT's P/E ratio is -15.87. In terms of profitability, LUCD's ROE is -4.04%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, LUCD is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
LUCD vs FOCL Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, FOCL has a market cap of 158.9M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while FOCL trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas FOCL's P/E ratio is -4.10. In terms of profitability, LUCD's ROE is -4.04%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, LUCD is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check FOCL's competition here
Inogen, Inc. (NASDAQ: INGN)
LUCD vs INGN Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, INGN has a market cap of 151.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while INGN trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas INGN's P/E ratio is -6.15. In terms of profitability, LUCD's ROE is -4.04%, compared to INGN's ROE of -0.13%. Regarding short-term risk, LUCD is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
LUCD vs QTRX Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, QTRX has a market cap of 147M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while QTRX trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas QTRX's P/E ratio is -1.23. In terms of profitability, LUCD's ROE is -4.04%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, LUCD is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check QTRX's competition here
Solana Company (NASDAQ: HSDT)
LUCD vs HSDT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, HSDT has a market cap of 108.6M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while HSDT trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas HSDT's P/E ratio is -0.02. In terms of profitability, LUCD's ROE is -4.04%, compared to HSDT's ROE of -1.23%. Regarding short-term risk, LUCD is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check HSDT's competition here
iCAD, Inc. (NASDAQ: ICAD)
LUCD vs ICAD Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas ICAD's P/E ratio is -20.37. In terms of profitability, LUCD's ROE is -4.04%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, LUCD is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
LUCD vs OWLT Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, OWLT has a market cap of 101.4M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while OWLT trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas OWLT's P/E ratio is -40.04. In terms of profitability, LUCD's ROE is -4.04%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, LUCD is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check OWLT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
LUCD vs HJLI Comparison August 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 183.2M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, LUCD is priced at $0.95 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.60, whereas HJLI's P/E ratio is N/A. In terms of profitability, LUCD's ROE is -4.04%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, LUCD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check HJLI's competition here